Form 4: Vir Biotechnology CEO Executes Estate Planning Transfer

CEO Marianne De Backer transferred 233,532 shares of Vir Biotechnology common stock to a family trust for estate planning.

Summary

• CEO Marianne De Backer transferred 233,532 shares of Vir Biotechnology common stock.
• The transaction involved moving shares from direct ownership to the Ureel-De Backer Family Trust.
• The transfer was executed without consideration for tax and estate planning purposes.
• Following the transaction, the CEO maintains direct ownership of 714,613 shares and indirect ownership of 286,650 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is purely administrative for estate planning purposes and does not represent a change in the CEO's total economic interest in the company.

Positives

• The transaction reflects long-term personal financial planning rather than a divestment of interest in the company.
• The CEO retains a significant beneficial interest in the shares through the family trust.

Negatives

• None.

Risks

• None.

Future Outlook

Not applicable.

Industry Context

StockSavvy.ai notes that internal share transfers for estate planning are standard corporate governance practices and do not typically signal changes in management confidence or company outlook.

Comparison to Industry Standards

• The transaction aligns with standard executive wealth management practices observed in the biotechnology sector.

Related Party Transactions

• Transfer of 233,532 shares to the Ureel-De Backer Family Trust, of which the Reporting Person and her spouse are Trustees.

Stakeholder Impact

• No material impact on shareholders, employees, or operations.

Key Dates

Keywords

Vir Biotechnology, VIR, Insider Trading, Form 4, Estate Planning, Marianne De Backer